LAUSR

Abstract This study provides insight into the overall system performance, stability, and delivery accuracy of the first clinical self‐shielded stereotactic radiosurgery (SRS) system. Quality assurance procedures specifically developed for this unit are discussed, and trends and variations over the course of 2‐years for beam constancy, targeting and dose delivery are presented. Absolute dose calibration for this 2.7 MV unit is performed to deliver 1 cGy/MU at dmax = 7 mm at a source‐to‐axis‐distance (SAD) of 450 mm for a 25 mm collimator. Output measurements were made with 2‐setups: a device that attaches to a fixed position on the couch (daily) and a spherical phantom that attaches to the collimating wheel (monthly). Beam energy was measured using a cylindrical acrylic phantom at depths of 100 (D10) and 200 (D20) mm. Beam profiles were evaluated using Gafchromic film and compared with TPS beam data. Accuracy in beam targeting was quantified with the Winston‐Lutz (WL) and end‐to‐end (E2E) tests. Delivery quality assurance (DQA) was performed prior to clinical treatments using Gafchromic EBT3/XD film. Net cumulative output adjustments of 15% (pre‐clinical), 9% (1st year) and 3% (2nd year) were made. The mean output was 0.997 ± 0.010 cGy/MU (range: 0.960–1.046 cGy/MU) and 0.993 ± 0.029 cGy/MU (range: 0.884–1.065 cGy/MU) for measurements with the daily and monthly setups, respectively. The mean relative beam energy (D10/D20) was 0.998 ± 0.004 (range: 0.991–1.006). The mean total targeting error was 0.46 ± 0.17 mm (range: 0.06–0.98 mm) for the WL and 0.52 ± 0.28 mm (range: 0.11–1.27 mm) for the E2E tests. The average gamma pass rates for DQA measurements were 99.0% and 90.5% for 2%/2 mm and 2%/1 mm gamma criteria, respectively. This SRS unit meets tolerance limits recommended by TG‐135, MPPG 9a., and TG‐142 with a treatment delivery accuracy similar to what is achieved by other SRS systems.